4.7 Review

Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Endocrinology & Metabolism

Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency

Yutaka Takahashi et al.

Summary: This study investigated the impact of long-acting growth hormone somapacitan on glucose metabolism in adult growth hormone deficiency patients. The results showed that somapacitan did not adversely affect glucose metabolism compared to daily growth hormone over 86 weeks.

PITUITARY (2023)

Article Endocrinology & Metabolism

Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement

Margaret C. S. Boguszewski et al.

Summary: Growth hormone replacement therapy is not associated with primary tumor or cancer recurrence. The risk of secondary neoplasia from GH replacement is minimal compared to other factors. GH replacement may be considered in adult cancer survivors in remission after careful risk/benefit analysis.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

Article Endocrinology & Metabolism

Dose-exposure-IGF-I response of once-weekly somapacitan in adults with GH deficiency

Rasmus Juul Kildemoes et al.

Summary: This study provides clinical guidance on dosing and titration of somapacitan in patients with adult growth hormone deficiency (AGHD) based on analyses of somapacitan dose-insulin-like growth factor I (IGF-I) responses. It supports higher starting doses for younger patients and women on oral estrogen therapy, and provides information on maintenance dose ratios and appropriate times for IGF-I sampling.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2022)

Article Endocrinology & Metabolism

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan

Rasmus Juul Kildemoes et al.

Summary: Linear models were developed to predict mean and peak IGF-I levels based on samples taken on different days after somapacitan administration, showing strong linear relationships between IGF-I sampled on any day and the weekly mean and peak levels. Monitoring IGF-I levels on day 4 and day 2 after dosing provided the most accurate estimates of mean and peak levels, respectively, offering a simple and reliable tool for optimal monitoring of IGF-I.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Review Medicine, General & Internal

Growth hormone deficiency in adults with hypopituitarism-What are the risks and can they be eliminated by therapy?

Gudmundur Johannsson et al.

Summary: GH deficiency is common in patients with hypothalamic-pituitary disorders, and its replacement therapy can improve symptoms and quality of life while maintaining a good safety profile.

JOURNAL OF INTERNAL MEDICINE (2021)

Editorial Material Endocrinology & Metabolism

The Use of IGF-I to Monitor Long-Acting Growth Hormone Therapy-Timing is an Art Comment

Martin Bidlingmaier et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

Review Endocrinology & Metabolism

Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs

Kevin C. J. Yuen et al.

Summary: Long-acting Growth Hormone (LAGH) analogs have been developed to reduce injection frequency and improve patient acceptance and therapeutic flexibility. However, potential clinical issues such as unphysiological GH profile, differing molecular structures, dose initiation, therapeutic monitoring, side-effect incidence, and long-term safety may arise with these analogs.

FRONTIERS IN ENDOCRINOLOGY (2021)

Article Endocrinology & Metabolism

Titrating Growth Hormone Dose to High-Normal IGF-1 Levels Has Beneficial Effects on Body Fat Distribution and Microcirculatory Function Despite Causing Insulin Resistance

Christa C. van Bunderen et al.

Summary: The study found that increasing IGF-1 levels had a beneficial effect on body composition but was detrimental to insulin resistance. At the same time, the contribution of the neurogenic vasomotion domain also increased.

FRONTIERS IN ENDOCRINOLOGY (2021)

Article Pharmacology & Pharmacy

Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials

Birgitte Bentz Damholt et al.

Summary: Two trials showed that exposure of somapacitan increased in patients with impaired kidney or liver function, leading to changes in IGF-I concentrations. This indicates that individualized dosage adjustments based on the kidney or liver conditions of patients are necessary when using somapacitan for those with growth hormone deficiency.

CLINICAL PHARMACOKINETICS (2021)

Review Endocrinology & Metabolism

GH Deficiency and Replacement Therapy in Hypopituitarism: Insight Into the Relationships With Other Hypothalamic-Pituitary Axes

Eriselda Profka et al.

Summary: Adult growth hormone deficiency is a complex condition often associated with multiple pituitary hormone deficiencies. Inappropriate replacement therapy can exacerbate symptoms, highlighting the crucial importance of a correct diagnosis.

FRONTIERS IN ENDOCRINOLOGY (2021)

Review Endocrinology & Metabolism

Long-Acting Growth Hormone Preparations - Current Status and Future Considerations

Bradley S. Miller et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)

Article Endocrinology & Metabolism

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial

Gudmundur Johannsson et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)

Review Endocrinology & Metabolism

Adult growth hormone deficiency: clinical advances and approaches to improve adherence

Kevin C. J. Yuen et al.

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM (2019)

Article Endocrinology & Metabolism

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

Gudmundur Johannsson et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)

Article Endocrinology & Metabolism

GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults

D. B. Allen et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)

Article Endocrinology & Metabolism

Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations

Jens Sandahl Christiansen et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)

Article Endocrinology & Metabolism

Compliance and Persistence in Pediatric and Adult Patients Receiving Growth Hormone Therapy

Ron Rosenfeld et al.

Endocrine Practice (2013)

Article Endocrinology & Metabolism

Adult Growth Hormone Deficiency – Benefits, Side Effects, and Risks of Growth Hormone Replacement

Mary L. Reed et al.

Frontiers in Endocrinology (2013)

Article Endocrinology & Metabolism

Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline

Mark E. Molitch et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)

Review Endocrinology & Metabolism

Estrogen regulation of growth hormone action

KC Leung et al.

ENDOCRINE REVIEWS (2004)